Scaling Cell Therapy Starting Material: What Changes From Phase I to Phase III

The Starting Material Problem Gets Harder at Every Phase

Early-phase cell therapy programs rarely budget for starting material scale-up. The focus is on the manufacturing process, the cell product, the efficacy signal. Starting material is a purchase order. It becomes a supply chain engineering problem by Phase III — and programs that didn’t build the supplier relationship for scale discover this at the worst possible time.

This guide maps what changes at each phase transition: regulatory expectations, collection volume requirements, supplier qualification depth, and the decisions made early that become constraints later.

Phase I: Establishing the Process

Starting material scope

Phase I cell therapy trials typically involve small patient cohorts — 15–30 patients for first-in-human autologous programs, larger for allogeneic off-the-shelf trials. Starting material volume is manageable. For autologous programs, each patient provides their own apheresis product. For allogeneic programs, a small number of healthy donor lots may supply the entire Phase I cohort.

GMP expectations at Phase I

The FDA’s expectations for GMP compliance in Phase I are calibrated to program maturity. Starting material at Phase I must meet basic quality standards — donor eligibility testing per 21 CFR 1271.85, collection procedures documented and controlled, and a basic CoA demonstrating the material was collected and processed appropriately. A full pharmaceutical-grade quality system is not required for Phase I, but the documentation infrastructure needs to be in place to support it at Phase II.

The decisions that matter at Phase I

Two decisions at Phase I have outsized downstream consequences:

• Supplier selection. The supplier you use at Phase I becomes the comparability reference point for every phase transition. Changing suppliers at Phase II requires a comparability study. Changing suppliers at Phase III — when you’re manufacturing for hundreds of patients and a BLA submission is in view — is a program-threatening event. Select the Phase I supplier as if you intend to use them at commercial scale, because the cost of switching later exceeds any Phase I cost savings.
• Documentation infrastructure. Batch records, donor history, collection records — establish the documentation system at Phase I that will scale to Phase III. Retrofitting a paper-based Phase I record system into a Phase III-ready quality system is expensive and disruptive. Start with the end in mind.

Phase II: Scaling Within the Same Supplier

Volume increases

Phase II cell therapy trials expand patient cohorts and often expand geographic reach. For autologous programs, starting material volume scales linearly with enrollment — more patients, more apheresis collections. Supplier capacity planning becomes an active requirement: how many collections can the supplier support per month, across how many sites, and with what scheduling lead time?

For allogeneic programs, Phase II may require additional manufacturing lots to support larger cohorts, which means additional healthy donor collections. Donor pool depth — the number of qualified, available donors — becomes a supply risk variable that wasn’t visible at Phase I.

Increased regulatory scrutiny

Phase II triggers more detailed FDA scrutiny of the CMC package. Starting material characterization expectations expand: the IND amendment for Phase II should include expanded lot history demonstrating process consistency, donor-to-donor variability data, and a more complete description of the supplier’s quality system. Any changes to the starting material since Phase I — different donor pool, modified processing parameters, new collection sites — require documented rationale and comparability assessment.

Supplier qualification update

If Phase I was conducted under a less formal supplier qualification framework, Phase II is the time to close those gaps. Execute or update the Quality Agreement. Conduct a formal supplier audit if one wasn’t done at Phase I. Review lot data against the acceptance criteria that will carry forward to Phase III and commercial.

Phase III and BLA Preparation: Supply Chain as a Regulatory Requirement

Commercial-scale volume planning

Phase III enrollment for CAR-T programs has ranged from 150 to 350+ patients depending on indication and study design. For autologous programs, this means 150–350+ apheresis collections, each processed and shipped on a patient-specific schedule to a manufacturing facility that may or may not be near the collection site. Supply chain management becomes equivalent in complexity to the manufacturing process itself.

BLA starting material section expectations

The BLA CMC section for a cell therapy product requires a comprehensive starting material description covering:

• Supplier identity, facility registration, and FDA inspection history
• Full collection and processing SOP summary
• Donor eligibility testing documentation
• Lot release criteria and testing methods with full validation summary
• Historical lot data demonstrating consistency over the BLA-supporting lot population
• Change control history — every change to starting material since IND, the comparability data supporting each change, and the regulatory correspondence documenting FDA’s acceptance

A supplier who has been the consistent supplier since Phase I has a clean, documented history to support all of this. A supplier transition at any point introduces a gap in that narrative that requires additional documentation and potentially raises questions during BLA review.

Multi-site collection network

Commercial cell therapy programs require collection at or near the treatment centers where patients are enrolled. For autologous programs, this means a national or global apheresis network — dozens to hundreds of collection sites with consistent quality standards, training, and documentation. The starting material supplier who was a single-site collection facility at Phase I needs to be, or be connected to, a multi-site network by BLA.

OrganaBio’s Cell Processing Center expansion model — Chicago currently, with additional cities in development — is specifically designed for this trajectory. Each new CPC adds geographic capacity without changing the core processing protocol or quality system. The same standards that produce consistent lot data in Chicago apply to each new CPC in the network.

Starting Material Supplier Selection: The Phase-Agnostic Criteria

Regardless of current program phase, evaluate starting material suppliers against criteria that matter at commercial scale, not just at your current scale:

• Geographic collection network size and expansion plan
• FDA registration and inspection history at the facility level
• GMP infrastructure status and Quality Agreement capability
• Lot-to-lot consistency data across the full lot history, not just recent collections
• Same-donor continuity capability (RUO-to-GMP within the same donor pool)
• Change control process and history of changes affecting product characterization
• Capacity ceiling: maximum collections per month and how demand spikes are handled

Contact OrganaBio’s scientific and commercial team to discuss how OrganaBio’s infrastructure and network expansion plan maps to your program’s Phase II and Phase III starting material requirements.

Frequently Asked Questions